Promethera Biosciences put out a press release today highlighting the phase 2a results for their stem cell based liver therapy, HepaStem.
The treatment targets ‘Acute-on-Chronic Liver Failure (ACLF) or acute decompensation (AD) at high risk of developing ACLF’, and aims to provide an alternative to liver transplantation by salvaging livers that are in the process of failing.
The therapy consists of liver stem cells obtained from healthy organs which are cultured to increase their numbers. The stem cells are then injected through the blood stream and ostensibly make their way through the liver to promote regeneration.
In this small study with 19 patients, the company proved that the treatment is well tolerated, and saw lasting improvements in MELD, Child-Pugh, and bilirubin levels at day 28, and up to three months after the initiation of treatment.
For more information, you can read Promethera’s press release here: https://www.promethera.com/sites/default/files/articles-2019-04/20190415_Promethera_EASL_Data_Update_EN_FINAL.pdf